Study title:
Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. von Minckwitz GRa, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al. Journal of Clinical Oncology~ 19(15):3506-3515, August 1, 2001 2001;(15):-3515, August.Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: A randomized, controlled, open phase IIb study. von Minckwitz GRa, Costa SD, Raab G, Blohmer JU, Eidtmann H, Hilfrich J et al. Journal of Clinical Oncology~ 19(15):3506-3515, August 1, 2001 2001;(15):-3515, August.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: TAMOXIFEN |
ATC code: L02BA01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|